NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), taking place from December 10-13, 2024. These clinical abstracts highlight the... Read More

NASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD, Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark “SecondReadAI” by Lunit, Inc. The corrected release follows: iCAD, Inc . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer... Read More

NASHUA, N.H., Nov. 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, December 1-5. Key highlights include the recent FDA-cleared ProFound Detection Version 4, clinical... Read More

NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3... Read More

NASHUA, N.H., Nov. 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation AI solution, trained using advanced deep learning... Read More

NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November... Read More

NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024. Earnings call details are as follows: Toll Free: 877-545-0320... Read More

Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a... Read More

NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform... Read More

NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will... Read More

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million,... Read More

NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062 International:... Read More

NASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windson g Radiology Group, one of US Radiology Specialists, Inc.’s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to... Read More

NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also... Read More

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial... Read More

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10% Total revenues were $5.0... Read More

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows:\ Domestic: 877-545-0523 International: 973-528-0016... Read More

NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523 International: 973-528-0016... Read More

ProFound Cloud, powered by Google Cloud architecture and Google’s Health AI innovations, redefines accessibility to critical insights, empowering radiologists in early breast cancer detection New partnership with Densitas provides end-to-end breast health solution ensuring every aspect of a woman’s breast health journey is addressed Enhanced ProFound Detection Workstation features streamline mammogram interpretation for... Read More

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation Expands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ:... Read More

NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered solution effectively uncovers calcium deposits in the breast vessels, a sign of possible cardiovascular disease in women. iCAD research collaborator Chirag Parghi , M.D., Chief Medical Officer of Solis Mammography ,... Read More

NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International . RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography... Read More

NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Breast Health Suite of AI solutions. “With the... Read More

NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced new, advanced workstation features for ProFound Detection for both 2D and 3D mammography in its latest V3 Service Pack update. “We're excited to introduce advanced workstation... Read More

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes,... Read More

Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially lower radiology reading workload Detection of Breast Arterial Calcification (BAC) by ProFound Heart Health could serve as biomarker to evaluate broader cardiovascular disease in women NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) --... Read More

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of... Read More

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time... Read More

NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 12-14, 2024, in... Read More

NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of... Read More

NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice President, North American Sales and a role change for Bill Keyes to Senior Vice President, Global Sales Operations, both effective immediately. “Together, Bill and Peter... Read More

Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite* AI applications streamline workflow and support clinicians in delivering more personalized breast care, including cancer detection, density assessment, and recommendations NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection... Read More

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast cancer iCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the U.S. Dr. Emily Conant, Perelman School of Medicine, University of... Read More

Offering radiology the most complete breast health solution, including breast density assessment, breast cancer detection, and thorough risk evaluation, including lifetime, genetic, and short-term 1- or 2-year AI-risk Partnership to expand access to ProFound Breast Health Suite and CancerIQ’s platform to benefit patients across thousands of facilities NASHUA, N.H. and CHICAGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc.... Read More

NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate at the 14 th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16... Read More

NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023. Highlights: Completed sale of Xoft, its therapy business line, to Elekta thereby enabling the Company to... Read More

NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that it will release financial results for the third quarter ended September 30, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, November 13, 2023.... Read More

NASHUA, N.H., Oct. 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions announced today that Elekta (EKTA-B.ST), the world leader in brachytherapy solutions, has agreed to acquire Xoft, a subsidiary of iCAD, Inc. for approximately $5.5 million and assumed liabilities. Elekta is taking over the business effective immediately and... Read More

NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD's personalized 1-2 year breast cancer risk assessment solution. "We are delighted to receive the device license from Health Canada for the... Read More

NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023. Highlights: iCAD signs 20-year worldwide development and commercialization agreement with Google Health to integrate Google’s AI technology with its... Read More

NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it signed an amendment to its development and commercialization agreement with Google Health , which will enable iCAD to integrate Google’s AI technology with its ProFound Breast Health Suite for 2D Mammography for use worldwide upon... Read More

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023. Earnings call details are as follows: Domestic: 888-506-0062 International: 973-528-0011 Participant... Read More

NASHUA, N.H., July 18, 2023 (GLOBE NEWSWIRE) -- i CAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a new strategic multi-year commercial agreement with Radiology Partners , the nation’s largest radiology practice through its owned and affiliated practices. Under the agreement, which was executed on June 27, Radiology... Read More

NASHUA, N.H., July 12, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr. Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is Finding the Breast Cancers Radiologists Fear the Most,” the live... Read More

NASHUA, N.H., July 10, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it is showcasing its ProFound AI Suite of clinically proven solutions for breast cancer detection, density assessment, and short-term risk evaluation in booth #228 at the AHRA 2023 annual meeting, taking place July 9-12 in Indianapolis, IN.... Read More

NASHUA, N.H., May 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its ProFound AI ® Breast Suite is a winner of the U.S. General Services Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio of breast cancer detection, density assessment and risk evaluation solutions at the... Read More

NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023. Highlights: ● Body of evidence supporting iCAD’s technologies grows, with compelling new research supporting Company’s Breast AI Suite and Xoft presented at key... Read More

NASHUA, N.H., May 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of non-melanoma skin cancer (NMSC). In the longest-term study of Xoft Skin eBx to-date, published in the Journal... Read More

NASHUA, N.H., May 03, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast AI Suite of cancer detection, density assessment and risk evaluation solutions at the world’s largest breast imaging conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7 in National... Read More

NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, May 15, 2023. Earnings call details are as follows: Domestic:... Read More

NASHUA, N.H., April 25, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy Schilling, MD, Medical Director, Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital. The live event, titled “Elevating Accuracy... Read More

NASHUA, N.H., April 20, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI ® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies. One study demonstrated that ProFound AI improved... Read More

NASHUA, N.H., April 17, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Eric Lonnqvist as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula as Chief Product Officer (CPO) and Michelle Strong as Chief Operations Officer (COO),... Read More

NASHUA, N.H., April 04, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new clinical evidence published in the Journal of Clinical Oncology found ProFound AI® Risk for 2D Mammography is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model, for both short-term and long-term risk assessments.... Read More

Strategy focused on profitability by end of 2024, using current cash on hand New leadership to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., March 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.... Read More

NASHUA, N.H., March 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its technologies are empowering customers to lead the way in breast care, while supporting the national breast density reporting standard recently established by the U.S. Food and Drug Administration (FDA). The Company will be showcasing... Read More

NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023. Based on preliminary, unaudited financial... Read More

Stacey Stevens Resigns as President and CEO and as a Member of the Board Dana Brown Named President and CEO, remains Chairman of the Board NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has accepted the resignation, for personal reasons, of Stacey Stevens as... Read More

NASHUA, N.H., March 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI® boosts radiologists’ efficiency and accuracy. The Company is also showcasing its Breast AI Suite of... Read More

NASHUA, N.H., Feb. 09, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023 in Snowbird, UT. Stacey Stevens, President and CEO of iCAD, Inc., will participate in one-on-one... Read More

Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA, N.H., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Daniel Shea, CPA, as interim Chief Financial Officer (CFO),... Read More

NASHUA, N.H., Jan. 11, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the appointment of Dana Brown as Executive Chair of the Board of Directors. Ms. Brown has been a non-executive board member since February 2022. Prior to joining iCAD’s board, Ms. Brown was the Senior Vice President, Chief Strategy and... Read More